BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis to $77 from $73 and keeps a Buy rating on the shares after the company reported preliminary Q4 Syfovre revenue of $114M that beat estimates. The firm is “encouraged” by a strong Q4 and “clear evidence of continued demand” and continues to look for color on the outcome of the EU regulatory process, which if positive could provide upside to its estimates, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
- Apellis Pharmaceuticals call volume above normal and directionally bullish